Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
ArgiNOx Phamaceuticals
company
About
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $8M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for the treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$33M
ArgiNOx Phamaceuticals has raised a total of
$33M
in funding over 2 rounds. Their latest funding was raised on
Mar 2, 2005 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 2, 2005 | Series C | $25M | 1 | — | — | Detail |
| Jun 12, 2004 | Series B | $8M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ArgiNOx Phamaceuticals is funded by 1 investors.
Perseus-Soros Biopharmaceutical Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Perseus-Soros Biopharmaceutical Fund
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
